Table 1 Subject characteristics
| Â | Control subjects (n = 20) | Idiopathic neuropathy subjects (n = 13) | Diabetes mellitus subjects (n = 82) | ||
|---|---|---|---|---|---|
| Â | Â | Â | Diabetes mellitus only (DM Only) (n = 12) | Diabetic peripheral neuropathy without neuropathic pain (DPN-NoP) (n = 23) | Diabetic peripheral neuropathy with neuropathic pain (DPN-P) (n = 47) |
Age | 58.5 ± 12.7 years | 60.7 ± 15.2 years | 53.6 ± 14.4 years | 61.1 ± 10.0 years | 59.8 ± 10.3 years |
Gender (males) | 4/20 (20%) | 6/13 (46%) | 6/12 (50%) | 16/23 (69%) | 30/47 (64%) |
Duration of Diabetes Mellitus |  |  | 7.2 ± 4.6 years | 8.6 ± 3.6 years | 9.1 ± 3.3 years |
Duration of Neuropathic Symptoms |  |  |  | 6.8 ± 4.2 years | 7.1 ± 4.7 years |
Concomitant Diabetic Complications Present (other than neuropathy) Concomitant Vascular Risk Factors: | Â | Â | 1/12 (8%) | 6/23 (26%) | 10/47 (21%) |
Hypertension | 3/20 (15%) | 3/13 (23%) | 8/12 (67%) | 17/23 (74%) | 21/47 (45%) |
Hyperlipidemia | 4/20 (20%) | 2/13 (15%) | 8/12 (67%) | 15/23 (65%) | 26/47 (55%) |
Family History of Peripheral Neuropathy | 0/20 (0%) | 0/13 (0%) | 0/12 (0%) | 0/23 (0%) | 0/47 (0%) |
Concomitant Statin Use | 4/20 (20%) | 2/13 (15%) | 7/12 (58%)* | 14/23 (61%)* | 23/47 (49%)* |
Hemoglobin A1C (%) (4.3-6.1%) | 5.2 ± 0.5 | 5.3 ± 0.8 | 7.4 ± 0.9* | 7.4 ± 1.3* | 7.8 ± 1.8* |
Total Cholesterol (4.2-5.2 mmol/L) | 4.5 ± 0.7 | 4.8 ± 0.8 | 3.8 ± 0.7 | 4.1 ± 1.0 | 4.2 ± 1.1 |
Triglycerides (0.6-2.3 mmol/L) | 1.2 ± 0.4 | 1.4 ± 1.4 | 1.3 ± 0.7 | 1.6 ± 0.8 | 2.0 ± 1.1* |
High Density Lipoprotein (>0.9 mmol/L) | 1.5 ± 0.5 | 1.5 ± 0.5 | 1.3 ± 0.4 | 1.2 ± 0.3 | 1.3 ± 0.7 |
Low Density Lipoprotein (2.2-3.4 mmol/L) | 2.9 ± 0.7 | 3.1 ± 1.1 | 2.2 ± 0.7 | 2.3 ± 0.9 | 2.3 ± 1.4 |
Toronto Clinical Neuropathy Score | 0.5 ± 1.1 | 8.3 ± 3.6 | 0.6 ± 1.1 | 10.8 ± 4.0 | 14.5 ± 5.3ψ |
Utah Early Neuropathy Score | 0.6 ± 1.9 | 7.9 ± 3.9 | 0.5 ± 1.0 | 10.4 ± 4.7 | 14.3 ± 7.8ψ |